Healthy
Conditions
Keywords
NLRP3, NLPR3 Inflammasone inhibitor
Brief summary
ZYIL1 is a novel oral selective NLRP3 inflammasome inhibitor which prevents NLRP3-induced ASC oligomerization, thus inhibiting NLRP3 inflammasome pathway. ZYIL1 is expected to show benefit in patients demonstrating cytokine, like IL1β flare, including those exhibiting cytokine storm related to COVID-19 and other viral inflammatory diseases.
Detailed description
It is an open label, study designed to evaluate safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) following a multiple-oral dose administration of ZYIL1 to healthy subjects aged between 18-55 years old (Both Inclusive). It will be conducted in up to 3 cohorts of 6 subjects each. Each cohort will be enrolled within a 28 day screening period to ensure subjects meet all the inclusion criteria and none of the exclusion criteria. Subjects will be administered multiple oral dose of ZYIL1 from day 1 to till day 14.
Interventions
DRUGZYIL1 Capsule
NLRP3 inflammasome inhibitor
Sponsors
Zydus Lifesciences Limited
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
A Phase I, Prospective, Open Label, Multiple Dose study
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
1. Healthy male or non-lactating non-pregnant female between 18 and 55 years of age at the time of signing the informed consent form (ICF). (Both inclusive). 2. Body mass index of 18.5 to 30.0 kg/m2 (Both inclusive) with a body weight of 50 to 100 kg (Both inclusive). 3. Normal QTc interval at screening and Check In \[QTcF ≤450 ms\] 4. Male subjects must agree to use adequate contraception methods during the study and be willing and able to continue contraception for 90 days after administration of study treatment. 5. Capable of giving written informed consent, which includes compliance with the study procedures, restrictions, and requirements listed in the protocol. 6. Subjects who, in the opinion of the Investigator, are healthy as determined by their pre study medical history, clinical examination, 12-lead ECG and clinical laboratory tests within the institutional normal range or judged as not clinically significant by the Investigator, including the following parameters: hematology, serum biochemistry, urinalysis, and serology. 7. Female subjects with history of sterility or at least 1 year menopause or use of long acting non hormonal contraceptive measures (e.g., intrauterine device) and be willing and able to continue contraception for 90 days after administration of study treatment.
Exclusion criteria
1. History or presence of alcoholism or drug abuse within the past 1 year. 2. Presence or history of any of the following disorders/disease within the past 3 months, that might have impact on the clinical trial as per the investigator discretion: cardiovascular, cerebrovascular, dermatological, gastrointestinal, gynecological, hematological, hepatic, malignancy, metabolic, musculoskeletal, neurological, urological, psychiatric, renal, respiratory, venereal, any other major disorders 3. History of clinically significant hypersensitivity, intolerance, or allergies, as determined by the Investigator. 4. History of COVID-19 infection within 14 days or contact with a confirmed active COVID-19 positive patient within 14 days; or positive COVID-19 test within 5 days of Check-in. . 5. History or presence of smoking or consumption of tobacco/nicotine products within the past 1 year. 6. Difficulty with donating blood. 7. Systolic blood pressure more than 140 mmHg or less than 100 mmHg or diastolic blood pressure more than 90 mmHg or less than 60 mmHg. 8. Pulse rate less than 55/minute or more than 100/minute. 9. Any clinically significant laboratory or ECG findings during screening 10. Surgery within last 3 months or planned major surgery within next 3 months from the date of screening (other than minor cosmetic surgery and minor dental surgery). 11. Subjects who have recent illness (eg, fever) within 14 days of check-in 12. Volunteers who have participated in any drug research study within past 3 months. 13. Volunteers who have donated one unit (350 ml) of blood in the past 3 months. 14. Has used prescription drugs and other substances (eg, dietary or herbal supplements such as St John's Wort) known to be either significant enzyme inducers or enzyme inhibitors within 4 weeks of Day 1, or use of grapefruit or similar substances (Seville oranges or marmalade, grapefruit juice, grapefruit hybrids, pomelos, exotic citrus fruits or fruit juices) within 7 days of Day 1. 15. Use of any over-the-counter (OTC), any prescription medications or alternative tradition of medicine (herbal medicines, homoeopathy, Siddha, Unani, etc.) within the 15 days or 5 half-lives (whichever is longer), prior to receiving study drug that might have impact on the clinical trial as per the investigator discretion. 16. A positive urine drugs of abuse test or positive alcohol test at check-in. 17. History of, or positive screening test for, hepatitis C infection (defined as positive for hepatitis C virus antibody), hepatitis B infection (defined as positive for hepatitis B surface antigen), or human immunodeficiency virus I or II. 18. Any disorder that, in the Investigator's opinion, may interfere with study compliance, such as significant mental, nervous disorder or other illness. In making this assessment, the Investigator must refer to the study information provided including the Investigator's Brochure. 19. Inability to be venipuncture or tolerate venous puncture. 20. Any condition or abnormal baseline findings that in the Investigator's judgment might increase the risk to the subject or decrease the chance of obtaining satisfactory data needed to obtain the objective of the study. 21. Other unspecified reasons that, in the opinion of the Investigator or the Sponsor, make the subject unsuitable for the study. 22. Female subjects who are pregnant, currently breastfeeding, or attempting to conceive.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence and Severity of Adverse event of ZYIL1 following a Multiple oral dose in healthy subjects | Baseline to Day 19 | he Common Terminology Criteria for Adverse Event (CTCAE) (Version 5.0 or higher) system will be used for reporting and grading |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Area under the curve from the time of dosing to the last measurable concentration (AUC0-t) | Day 1 to Day 16 | At each dose level, blood samples will be withdrawn for the evaluation of pharmacokinetic. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Cmax,ss | Day 1 to Day 16 | At each dose level, blood samples will be withdrawn for the evaluation of pharmacokinetic. |
| Cmin,ss | Day 1 to Day 16 | At each dose level, blood samples will be withdrawn for the evaluation of pharmacokinetic. |
| Accumulation Index | Day 1 to Day 16 | At each dose level, blood samples will be withdrawn for the evaluation of pharmacokinetic. |
| % Fluctuation | Day 1 to Day 16 | At each dose level, blood samples will be withdrawn for the evaluation of pharmacokinetic. |
| Tmin,ss | Day 1 to Day 16 | At each dose level, blood samples will be withdrawn for the evaluation of pharmacokinetic. |
Countries
India
Outcome results
None listed